key: cord-0977209-bdxd5uxk
authors: Xiang, Jingyu; Lu, Mijia; Shi, Min; Cheng, Xiaogang; Kwakwa, Kristin A.; Davis, Jennifer L.; Su, Xinming; Bakewell, Suzanne J.; Zhang, Yuexiu; Fontana, Francesca; Xu, Yalin; Veis, Deborah J.; DiPersio, John F.; Ratner, Lee; Sanderson, Ralph D.; Noseda, Alessandro; Mollah, Shamim; Li, Jianrong; Weilbaecher, Katherine N.
title: Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19
date: 2022-03-23
journal: Journal of virology
DOI: 10.1128/jvi.00057-22
sha: 896045c5351fec8a6465f0d33a1a8f5e5f51b310
doc_id: 977209
cord_uid: bdxd5uxk

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 5 million deaths worldwide. Pneumonia and systemic inflammation contribute to its high mortality. Many viruses use heparan sulfate proteoglycans as coreceptors for viral entry, and heparanase (HPSE) is a known regulator of both viral entry and inflammatory cytokines. We evaluated the heparanase inhibitor Roneparstat, a modified heparin with minimum anticoagulant activity, in pathophysiology and therapy for COVID-19. We found that Roneparstat significantly decreased the infectivity of SARS-CoV-2, SARS-CoV-1, and retroviruses (human T-lymphotropic virus 1 [HTLV-1] and HIV-1) in vitro. Single-cell RNA sequencing (scRNA-seq) analysis of cells from the bronchoalveolar lavage fluid of COVID-19 patients revealed a marked increase in HPSE gene expression in CD68(+) macrophages compared to healthy controls. Elevated levels of HPSE expression in macrophages correlated with the severity of COVID-19 and the expression of inflammatory cytokine genes, including IL6, TNF, IL1B, and CCL2. In line with this finding, we found a marked induction of HPSE and numerous inflammatory cytokines in human macrophages challenged with SARS-CoV-2 S1 protein. Treatment with Roneparstat significantly attenuated SARS-CoV-2 S1 protein-mediated inflammatory cytokine release from human macrophages, through disruption of NF-κB signaling. HPSE knockdown in a macrophage cell line also showed diminished inflammatory cytokine production during S1 protein challenge. Taken together, this study provides a proof of concept that heparanase is a target for SARS-CoV-2-mediated pathogenesis and that Roneparstat may serve as a dual-targeted therapy to reduce viral infection and inflammation in COVID-19. IMPORTANCE The complex pathogenesis of COVID-19 consists of two major pathological phases: an initial infection phase elicited by SARS-CoV-2 entry and replication and an inflammation phase that could lead to tissue damage, which can evolve into acute respiratory failure or even death. While the development and deployment of vaccines are ongoing, effective therapy for COVID-19 is still urgently needed. In this study, we explored HPSE blockade with Roneparstat, a phase I clinically tested HPSE inhibitor, in the context of COVID-19 pathogenesis. Treatment with Roneparstat showed wide-spectrum anti-infection activities against SARS-CoV-2, HTLV-1, and HIV-1 in vitro. In addition, HPSE blockade with Roneparstat significantly attenuated SARS-CoV-2 S1 protein-induced inflammatory cytokine release from human macrophages through disruption of NF-κB signaling. Together, this study provides a proof of principle for the use of Roneparstat as a dual-targeting therapy for COVID-19 to decrease viral infection and dampen the proinflammatory immune response mediated by macrophages.

responsible for binding to antithrombin (18) . The resulting diminished antithrombin binding activity of the glycol-split heparin greatly diminishes its anticoagulant activity, thus allowing the utilization of the drug at high doses in patients. At the preclinical stage, Roneparstat also showed therapeutic benefit in multiple inflammatory disease models such as acute pancreatitis and acute kidney injury (19) . In a phase I clinical trial (ClinicalTrials.gov identifier NCT01764880) in patients with advanced MM, Roneparstat was well tolerated and safe at all doses tested, with no dose-limiting toxicities (20) .

In this study, we set out to investigate the role of heparanase in the pathogenesis of COVID-19 and evaluate Roneparstat as a novel therapy. In line with the role of HSPGs as coreceptors for viral entry, we found that treatment with heparin or Roneparstat effectively decreased the infectivities of SARS-CoV-2 as well as the retroviruses HTLV-1 and HIV-1 in vitro. Using HIV-1Denv pseudotyped with vesicular stomatitis virus G (VSVg) envelope, an HSPG-independent pseudotyped virus, we further showed that the antiviral activity of Roneparstat is specific to HSPG-mediated viral entry. Single-cell RNA sequencing (scRNAseq) analysis of cells isolated from bronchoalveolar lavage fluid (BALF) of COVID-19 patients showed elevated levels of HPSE gene expression compared to healthy controls. In addition, we found that HPSE expression was almost exclusively upregulated in CD68 1 macrophages and correlated with disease severity and multiple inflammatory cytokine genes, including IL6, IL1B, and TNF. In primary human macrophages, SARS-CoV-2 S protein challenge induced the expression of HPSE and inflammatory cytokines. The knockdown (KD) of HPSE in human macrophages attenuated the induction of multiple inflammatory cytokines by SARS-CoV-2 S1 protein, suggesting that HPSE plays an important role in the induction of these inflammatory cytokines in macrophages. We further demonstrated that heparanase blockade with Roneparstat attenuated the production of the inflammatory cytokines in a dose-dependent manner via disruption of NF-k B signaling. Overall, this study provides a proof of principle for the use of Roneparstat as a dual-targeting therapy for COVID-19 to decrease viral infection and dampen the proinflammatory immune response mediated by macrophages.

The heparanase inhibitor Roneparstat decreases SARS-CoV-2 infectivity. Heparan sulfate (HS) is an important cofactor for the attachment and entry of multiple viruses, including SARS-CoV-2 (8, 9) . To test whether Roneparstat could suppress SARS-CoV-2 S protein-mediated entry, we first used a replication-competent VSV-SARS-CoV-2 chimeric virus (VSV-eGFP-SARS-CoV-2), in which the VSV G gene was replaced by the SARS-CoV-2 S gene (Fig. 1A ). In this model, Vero-E6 cells were infected by VSV-eGFP-SARS-CoV-2 (multiplicity of infection [MOI] = 0.1) in the presence of various doses of Roneparstat or heparin for 1 h. At 10 h postinfection, green fluorescent protein-positive (GFP 1 ) cells were quantified. Treatment with Roneparstat or heparin resulted in a significant dose-dependent decrease in infected cells ( Fig. 1B and C) , with half-maximal inhibitory concentrations (IC 50 s) of 0.05 mg/mL and 0.03 mg/mL, respectively ( Fig. 1D and E). Similar inhibitory effects on infectivity were observed in Vero-E6 cells infected with the VSV-eGFP-SARS-CoV-1 chimeric virus in which VSV G was replaced with the SARS-CoV-1 S gene (Fig. 1F to J), suggesting that Roneparstat and heparin inhibit cell entry mediated by S protein.

We next examined the effect of Roneparstat and heparin during SARS-CoV-2 infection in Vero-E6 cells. Vero-E6 cells were infected with SARS-CoV-2 in the presence of various doses of Roneparstat or heparin for 1 h. At 24 h postinfection, the cell culture supernatant from each well was harvested for virus titration by a plaque assay on Vero-E6 cells. SARS-CoV-2-infected Vero-E6 cells were immunostained with specific anti-spike (S) or -nuclear (N) protein antibody ( Fig. 1K and L). In line with what we observed in the VSV-eGFP-SARS-CoV-2 infection assay, both Roneparstat and heparin treatment significantly decreased SARS-CoV-2 infection, with IC 50 s of 0.07 mg/mL and 0.05 mg/mL, respectively ( Fig. 1M and N) . Together, these data demonstrated that Roneparstat is potent against SARS-CoV-2 infection in vitro. Roneparstat blocks HSPG-dependent viral entry. To rule out that the reduction of infectivity was due to the potential cytotoxicity of Roneparstat, we examined the viability of cells treated with various doses (up to 200 mg/mL) of Roneparstat. As measured by cell viability assays, no cytotoxicity was observed in multiple cell lines (Vero-E6, Jurkat, and THP-1) treated with Roneparstat ( Fig. 2A to C). HSPG is known as one of the coreceptors for SARS-CoV-2 and HTLV-1 viral entry (8) . Therefore, we further extended our analysis to the infectivity of retroviruses, including HTLV-1 and HIV-1. Jurkat T cells, engineered to express the luciferase (Luc) gene driven by the HTLV-1 long terminal repeat (LTR), were cocultured with the HTLV-1-producing cell line MT-2 for 48 h in the presence or absence of various doses of Roneparstat. Similarly, TZM-Blue cells engineered to express luciferase driven by the HIV-1 LTR were pretreated with various doses of Roneparstat and infected with HIV-1 for 24 h. In both experiments, Roneparstat treatment significantly decreased infection by HTLV-1 (Fig. 2D ) and HIV-1 (both CXCR4-and CCR5-tropic strains) ( Fig. 2E and F) . Conversely, infection by VSV is independent of the HSPG-mediated viral entry mechanism (21, 22) . To confirm that the reduction of infectivity by Roneparstat was HSPG dependent, we constructed HSPG-independent VSVg-HIV-1Denv pseudotyped virus by cotransfecting HIV-1-luc/ Denv (HIV-1 with defective envelope) with VSVg. CXCR4-expressing U87/X4 or CCR5expressing U87/R5 target cells were infected with VSVg-HIV-1Denv-luc in the presence or absence of Roneparstat for 48 h. No reduction of infectivity was observed in either U87/X4 or U87/R5 cells infected with VSVg-HIV-1Denv-luc ( Fig. 2G and H), suggesting that Roneparstat-mediated blockade of infectivity is through HSPGs. Together, these data demonstrated that treatment with Roneparstat or heparin decreases the infectivity of a broad spectrum of viruses, including SARS-CoV-1, SARS-CoV-2, HTLV-1, and HIV-1, in vitro through an HSPG-dependent viral entry mechanism.

Upregulation of heparanase expression in pulmonary macrophages from COVID-19 patients. Increased plasma levels of heparanase were reported in COVID-19 patients (16) . Seeking to identify the cells that expressed the HPSE gene in COVID-19 patients, we analyzed the single-cell RNA sequencing (scRNA-seq) data set (GEO accession number GSE145926) from cells harvested from the bronchoalveolar lavage fluid (BALF) of moderate or severe COVID-19 patients and healthy volunteers (23) . HPSE gene expression was upregulated in various BALF cell populations of patients with COVID-19, especially those with severe COVID-19 (Fig. 3A) . Specifically, HPSE was highly expressed in the macrophage population (CD68 1 ), with modest increases in T cells (CD3D 1 ), epithelial cells (TPPP3 1 KRT18 1 ), and myeloid dendritic cells (mDCs) (CD1C 1 CLEC9A 1 ) in patients with severe COVID-19 compared to the healthy controls and those with moderate disease (Fig. 3B ). Further analysis of the CD68 1 macrophage population demonstrated that the expression levels of HPSE, along with inflammatory cytokine genes such as IL6, TNF, IL1B, and CCL2, increased with the disease severity of COVID-19 ( Fig. 3C to G). Inflammatory cytokines such as IL-6 and tumor necrosis factor alpha (TNF-a) are critical players during the inflammation phase of COVID-19 (24) . Spearman's correlation coefficient test between HPSE and the inflammatory cytokine genes IL6, TNF, IL1B, and CCL2 showed a significant positive correlation ( Fig. 3H to K). These data confirmed that HPSE is upregulated in the macrophages of COVID-19 patients and is associated with inflammatory cytokine release. Inhibition of HPSE enzyme activity with Roneparstat decreases inflammatory cytokine release induced by SARS-CoV-2 spike protein in human primary macrophages. The binding of SARS-CoV-2 to host cell coreceptors is mediated by the receptor binding domain (RBD) in the S1 subunit of the spike protein. To test whether S1 protein is Cell markers (cell types are identified by signature genes) for each cell type are defined as follows: CD68 for macrophages, TPSB2 for mast cells, MS4A1 for B cells, IGHG4 for plasma cells, KLRD1 for natural killer (NK) cells, FCGR3B for neutrophils, LILRA4 for plasmacytoid dendritic cells (pDC), CD3D for T cells, TPPP3 and KRT18 for epithelial cells, and CD1C and CLEC9A for myeloid dendritic cells (mDC). (C to G) Expression levels of HPSE, IL6, TNF, IL1B, and CCL2 by BALF macrophages across healthy control, moderate COVID-19, and severe COVID-19 samples. (H to K) Correlations between HPSE expression and the expression of IL6, TNF, IL1B, and CCL2. Error bars represent the SEM. *, P , 0.05; **, P , 0.01; ***, P , 0.001 (2-tailed distribution, homoscedastic Student's t test for 2 groups or 1-way ANOVA for multiple comparisons; a Spearman correlation coefficient test was adopted to determine statistically significant correlations between two groups). sufficient to trigger inflammatory cytokine release and HPSE expression, we used a macrophage challenge model. Human primary macrophages were differentiated from monocytes from healthy human donors in vitro and subsequently challenged with SARS-CoV-2 S1 protein overnight (Fig. 4A ). Gene expression analysis by quantitative PCR (qPCR) revealed a significant upregulation of HPSE, IL6, TNF, CCL2, and IFNG after S1 protein challenge (Fig. 4B ). To evaluate whether heparanase can regulate the expression of inflammatory cytokine genes such as IL-6, in parallel with S1 protein challenge, we treated macrophages with various doses of active recombinant human heparanase for 12 h and examined the IL-6 expression level by qPCR. Treatment with exogenous heparanase induced elevated levels of IL-6 expression, at levels similar to those seen with S1 protein stimulation (Fig. 4C ). Next, to examine whether HPSE blockade could suppress the induction of inflammatory cytokines, we challenged macrophages with S1 protein, in the presence or absence of various doses of Roneparstat. Indeed, treatment with Roneparstat resulted in a dose-dependent reduction in the expression of inflammatory cytokine genes such as IL6, TNF, CCL2, and IFNG ( Fig. 4D to G). Using a flow cytometry-based multiplex inflammatory cytokine array, we showed that HPSE blockade with Roneparstat also significantly attenuated the protein levels of multiple inflammatory cytokines, including IL-6, TNFa, IL-10, IL-1b, IL-23, IL-33, and IL-12p70 ( Fig. 4H to N). In contrast, no significant changes were seen in interferon gamma (IFN-g), IFN-a2, monocyte chemoattractant protein 1 (MCP-1), IL-8, IL-17A, and IL-18 (data not shown). These experiments demonstrated that S1 protein alone is sufficient to induce the upregulation of heparanase, which promotes the production of inflammatory cytokines. HPSE blockade with Roneparstat dampens inflammatory cytokine release induced by SARS-CoV-2 S1 protein in macrophages.

SARS-CoV-2 spike protein-induced inflammatory cytokine release is partially mediated by HPSE. Heparanase is important for macrophage activation (25) . To further investigate the proinflammatory role of HPSE in macrophages in the context of SARS-CoV-2, we knocked down the HPSE gene in the human macrophage cell line THP-1 using short hairpin RNA (shRNA) with a 60% average knockdown efficiency (Fig.  5A ). THP-1 cell-derived macrophages were challenged with S1 protein (0.5 mg/mL). The knockdown of HPSE in THP-1 macrophages prevented the induction of IL6 or IL1B gene expression ( Fig. 5B and C). At the protein level, using a flow cytometry-based multiplex inflammatory cytokine array, we found marked increases in multiple inflammatory cytokines (IL-6, TNF-a, MCP-1, and IL-1B) in the conditioned medium from the S1-stimulated THP-1 cells but at much lower levels in the stimulated HPSE knockdown lines ( Fig. 5D to H). These data suggest that HPSE plays an important role in the induction of inflammation cytokines in macrophages upon S1 protein challenge.

Roneparstat decreases SARS-CoV-2 spike protein-induced inflammatory cytokine release via NF-jB signaling. NF-k B signaling is a master regulator of inflammation, which regulates the transcription of several cytokines (26) . To test whether the induction of the inflammatory cytokines by SARS-CoV-2 spike protein was dependent on NFk B signaling, human macrophages were pretreated with the NF-k B inhibitor BAY-11-7082 (BAY) for 1 h, followed by S1 protein challenge. Treatment with BAY suppressed S1 protein-induced inflammatory cytokine gene expression (IL6, TNF, IL1B, and CCL2) in a dose-dependent manner ( Fig. 6A to D). At steady state, cytosolic NF-k B p65 is retained in an inactive form and is targeted by E3 ligases for degradation (27) . In response to proinflammatory signals, p65 translocates from the cytoplasm to the nucleus, where it is stabilized and activates the transcription of inflammatory cytokine genes. In macrophages, p65 also induces its own transcription, further increasing the nuclear occupancy of p65 and, consequently, cytokine production (26) . Immunostaining of p65 in primary macrophages stimulated with S1 protein showed an overall increase of p65, with a significant increase in nuclear occupancy, as measured by the nuclear mean fluorescence intensity (MFI). Cotreatment with Roneparstat showed a dose-dependent reduction in nuclear p65 ( Fig. 6E and F). The reduction of nuclear and cytoplasmic NF-k B (p65) was also confirmed by Western blotting (Fig. 6G to I) . Together, these data demonstrated that in macrophages , and IFNG genes in macrophages challenged with S1 protein (0.5 mg/mL) for 12 h. (C) qPCR detection of the transcription of IL-6 in macrophages challenged with S1 protein (0.5 mg/mL) or various doses (100, 200, and 300 ng/mL) of recombinant active heparanase (rHPSE) for 12 h. (D to G) qPCR detection of the transcription of the IL6, TNF, CCL2, and IFNG genes in macrophages cotreated with S1 protein (0.5 mg/mL) and various doses of Roneparstat (50 and 200 mg/mL) for 12 h. (H) Conditioned medium was collected from the macrophages cotreated with S1 protein (0.5 mg/mL) and various doses of Roneparstat (100 and 200 mg/mL) for 24 h. Inflammatory cytokines were quantified using a flow cytometry-based multiplex cytokine array. Fold changes of the secreted inflammatory cytokines were normalized to the values for the untreated control and are presented in a heat map. (I to N) Absolute concentrations of secreted TNF-a, IL-6, IL-10, IL-1b, IL-33, and IL-23 were calculated based on standard curve fitting. Error bars represent the SEM. *, P , 0.05; **, P , 0.01; ***, P , 0.001 (2-tailed distribution, homoscedastic Student's t test for 2 groups or 1-way ANOVA for multiple comparisons). challenged with SARS-CoV-2 S1 protein, Roneparstat treatment reduced NF-k B-dependent induction of inflammatory cytokines.

To date, COVID-19 has caused over 5 million deaths worldwide. However, while the development and deployment of vaccines are ongoing, effective therapy for COVID-19

FIG 5 SARS-CoV-2 S1-induced inflammatory cytokine release depends on HPSE expression. Control (shLuc) or HPSE knockdown (KD) THP-1-derived macrophages were challenged with S1 protein (0.5 mg/mL) for 12 h. (A to C) Transcription levels of HPSE (A), IL6 (B), and IL1B (C) were examined by qPCR. (D) Conditioned medium was collected from the THP-1 macrophages treated with S1 protein (0.5 mg/mL) for 24 h. Inflammatory cytokines were quantified using a flow cytometry-based multiplex cytokine array. Fold changes of the secreted inflammatory cytokines were normalized to the values for the untreated control and are presented in a heat map. (E to H) Absolute concentrations of secreted IL-6 (E), TNF-a (F), MCP-1 (G), and IL-1b (H) were calculated based on standard curve fitting. Error bars represent the SEM. *, P , 0.05; **, P , 0.01; ***, P , 0.001 (2-tailed distribution, homoscedastic Student's t test for 2 groups or 1-way ANOVA for multiple comparisons).

Heparanase Blockade in COVID- 19 Journal of Virology is still urgently needed. In this study, we sought to evaluate the role of heparanase in COVID-19 disease pathology and to evaluate Roneparstat, a chemically modified heparin that is a potent inhibitor of heparanase enzyme activity without anticoagulant activity, as a novel dual-targeting therapy for COVID-19. Many viruses, including SARS-CoV-2, are known to utilize heparan sulfate (HS) to attach to the host target cell. In line with these findings, we found that treatment with Roneparstat significantly decreased infection by coronaviruses, including SARS-CoV-2 and SARS-CoV-1, as well as retroviruses, including HTLV-1 and HIV-1, in vitro. From scRNA-seq analyses of bronchoalveolar lavage fluid (BALF) samples from COVID-19 patients, we found that heparanase gene (HPSE) expression was significantly upregulated in CD68 1 bronchial macrophages in COVID-19 patients with moderate and severe disease. To evaluate the role of heparanase in macrophages and inflammation in COVID-19, we stimulated human macrophages with SARS-CoV-2 S1 protein and found significant induction of heparanase and other key inflammatory cytokines. Importantly, we found that pharmacological blockade of heparanase with Roneparstat suppressed inflammatory cytokine production in response to SARS-CoV-2 S1 protein challenge, through decreased NF-k B signaling.

A recent structural analysis revealed that heparin, a structural analog of HS, can bind to the receptor binding domain (RBD) of the SARS-CoV-2 S1 protein, inducing a distinct conformational change (28) . The interaction between heparin and the SARS-CoV-2 spike protein was also confirmed by competitive binding assays, showing that heparin can bind at high-picomolar affinity (29) . Our data revealed that both heparin and Roneparstat potently decreased infection by SARS-CoV-2 in Vero-E6 cells. Using the VSV-eGFP-SARS-CoV-2 chimeric virus, we observed similar potency of Roneparstat or heparin in blocking infectivity, indicating that one of the main mechanisms leading to reduced infectivity could be through Roneparstat competitive disruption of SARS-CoV-2 spike protein binding to cell surface HS. An extended analysis of Roneparstat and infectivity using other RNA viruses, including VSV-eGFP-SARS-CoV-1 chimeric virus and pathogenic HIV-1 and HTLV-1, also showed the efficacy of Roneparstat in reducing infection. Importantly, Roneparstat failed to decrease the infectivity of VSVg-HIV-luc-Denv, an HSPG-independent pseudotyped HIV-1. These data suggest that the reliance on HSPGs to enter the target cell may be a common phenomenon among these RNA viruses. Although beyond the scope of this study, we are designing experiments to determine if Roneparstat interferes with the RBD of the SARS-CoV-2 spike protein, as has been observed with heparin.

Heparanase regulates the availability of HS on the cell surface or within the extracellular matrix. Upregulation of heparanase has been primarily studied for its role in cancer progression (12) . In recent years, accumulating evidence suggests that HPSE is also involved in viral disease pathogenesis (30) . In HSV-1-associated disease, the upregulation of HPSE after HSV-1 infection promoted virus shedding and the production of proinflammatory cytokines (31, 32) . Another recent study reported by Agelidis et al. demonstrated that cells lacking HPSE expression are intrinsically resistant to HSV-1 infection. In the corneal infection model, HPSE knockout mice also had decreased virus titers and associated inflammation (33) . The role of heparanase in viral pathogenesis is likely due to the multiple effects of this enzyme. Once new virus is produced, during its egress from the cell, it can be trapped on the cell surface by heparan sulfate-bearing cell surface proteoglycans, including syndecan-1. Heparanase stimulated by viral infection degrades cell surface heparan sulfate chains, thereby facilitating the release of the virus bound to those chains (30) . An additional role for heparanase in viral egress lies in its ability to stimulate the shedding of heparan sulfate proteoglycans from the cell surface. It was previously demonstrated that the expression of heparanase by myeloma cells upregulates extracellular signal-regulated kinase (ERK) signaling, leading to the expression of the syndecan-1 sheddase matrix metalloproteinase 9 (MMP-9) (34) . Similarly, during HSV-1 infection, heparanase induces the expression of MMP-3 and MMP-7, which leads to the shedding of cell surface syndecan-1 and the virus that is bound to the heparan sulfate chains (35) .

The addition of purified recombinant heparanase resulted in macrophage activation and the upregulation of inflammatory cytokines, including IL-6 (36). Macrophages from heparanase knockout (Hpa-KO) mice also expressed lower levels of inflammatory cytokines (e.g., IL-6, TNF-a, and IL-1b) (25) , and the overexpression of Hpse exacerbated inflammatory cytokine production in an ulcerative colitis model (13) . Buijsers et al. recently reported that elevated plasma levels of heparanase were detected in hospitalized patients with COVID-19 (16) , but the source of heparanase has not been defined. In our studies, single-cell RNA-seq analysis of cells harvested from BALF enabled us to identify macrophages as the primary source of heparanase. In a recent report by Abdelmoaty et al. (37) , it was shown that human macrophages were infected by live SARS-CoV-2. Although infection of macrophages by SARS-CoV-2 is restrictive without evidence of replication, mature virions showed long persistence (14 days after initial exposure). In addition, persistent SARS-CoV-2 components in macrophages induced the production of multiple proinflammatory cytokines such as IL-6, IL-1b, and TNF-a, similar to what we have shown with the SARS-CoV-2 S1 protein, and HPSE knockdown in THP-1-derived macrophages resulted in a significant attenuation of inflammatory cytokines, highlighting the pivotal role of HPSE in the induction of inflammation. Together, these data demonstrated the multifaceted roles of heparanase in both infection and inflammation.

A subset of COVID-19 patients progress to a severe stage, characterized by dysregulated inflammatory cytokine release that causes tissue injury, acute respiratory distress syndrome (ARDS), and death. The hyperinflammatory state in patients with severe COVID-19 resembles cytokine release syndrome (CRS), which is seen in patients receiving chimeric antigen receptor (CAR) T-cell therapy (5) . The overproduction of IL-6 by monocytes/macrophages has emerged as a key driver of CRS. Tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, has been evaluated in large randomized clinical trials. While some trials (RECOVERY and REMAP-CAP trials) showed a survival benefit, others, including the COVACTA trial, showed a limited or no benefit in patient mortality (38, 39) . These disparate results may be due to multiple factors, such as the timing of the treatment, the patient population, and the use of glucocorticoids. This may also indicate that targeting a single inflammatory cytokine may not be sufficient to suppress the overall inflammatory disease progression in COVID-19. In our cytokine screening of a panel of common proinflammatory cytokines, we found elevations of numerous inflammatory cytokines other than IL-6 after S1 protein challenge that were blocked by Roneparstat, suggesting that targeting heparanase could be a viable therapeutic approach for inhibiting inflammatory cytokine release in COVID-19.

The NF-k B signaling pathway is the main regulator of the production of inflammatory cytokines during the innate immune response. Wang et al. reported that the SARS-CoV-1 spike protein induced IL-6 and TNF-a production by activating NF-k B (40) . IL-6 is the main stimulator of STAT3, which allows the full activation of the NF-k B signaling pathway (41) . TNF-a also promotes the activation of noncanonical NF-k B signaling. In the case of hyperinflammation, these interactions result in a vicious cycle of NFk B hyperactivation fueling the production and release of more inflammatory cytokines. In our study, Western blot assays as well as immunofluorescence staining of NF-k B (p65) in macrophages showed increased p65 expression in both the cytoplasmic and nuclear compartments, suggesting that the spike protein is a strong activator of NF-k B signaling. Treatment with Roneparstat decreases both the cytoplasmic and nuclear p65 levels, suggesting that heparanase inhibition could prevent the induction of the expression of p65. Studies are under way to evaluate NF-k B signaling in infection and pathogenesis models in vivo.

Pulmonary activation of coagulation pathways is common in severe COVID-19, evidenced by the elevated levels of D-dimer and fibrin degradation product (FDP) (42) . Patients with severe COVID-19 are at an increased risk of venous thromboembolism and microthrombosis. Disseminated intravascular coagulation (DIC) was reported in 71.4% of nonsurvivors versus 0.6% of survivors among patients diagnosed with COVID-19 (43) . Anticoagulant therapy such as heparin was recommended for COVID-19 patients with hypercoagulable syndromes. From one retrospective study, treatment with low-molecular-weight heparin (LMWH) resulted in lower serum IL-6 levels in COVID-19 patients (44) . No therapeutic benefit of heparin was observed in COVID-19 patients with critical disease (45) . In COVID-19 patients with moderate disease, therapeutic doses of heparin increased the probability of survival and reduced the use of cardiovascular or respiratory organ support, compared with the usual-care thromboprophylaxis (46) . The therapeutic dose of heparin, however, is associated with a 10 to 15% risk of significant bleeding. Factors increasing the risk of bleeding include older age, anemia, recent trauma or surgery, hypertension, and renal insufficiency. Many of these risk factors are common in patients with severe COVID-19. In contrast, Roneparstat is a chemically modified heparin that caused little to no bleeding complications in a phase I clinical trial at all doses tested. In our infectivity assay, Roneparstat showed activity comparable to that of unfractionated heparin in the SARS-CoV-2 infectivity assay. An open-label, multicenter phase I clinical trial (ClinicalTrials.gov identifier NCT01764880) was carried out to evaluate the safety and tolerability of Roneparstat in patients with relapsed/refractory multiple myeloma. Roneparstat was well tolerated in patients, with no dose-limiting toxicities (20) . Future studies are under way to examine the tolerability and efficacy of Roneparstat in SARS-CoV-2 animal models.

COVID-19 consists of two main pathogenic phases, progressing from the initial infection response phase dominated by SARS-CoV-2 entry and replication to the inflammatory response phase dominated by the host immune response. The current standard COVID-19 therapy includes antiviral therapy with remdesivir and anti-inflammatory drugs such as dexamethasone to decrease disease severity but showed less optimal results in reducing mortality. While cytokines produced during the infection may contribute to the worsening of the disease, they could also be important for the antimicrobial response. Therefore, blocking of inflammatory cytokine release alone at the early stage may impair the clearance of the virus and lead to delayed recovery from the disease. This might partially explain the poorer outcomes in mild COVID-19 patients receiving dexamethasone in the RECOVERY trial (ClinicalTrials.gov identifier NCT04381936) (47) . The dual-targeting effect of Roneparstat on both viral infection and macrophage-mediated inflammatory cytokine release (Fig. 7) and its safe profile in patients could be advantageous in this setting. Beyond the scope of COVID-19, HPSE may also play a role in other RNA virus-mediated diseases, such as respiratory syncytial virus (RSV) (48) . Studies are under way to evaluate Roneparstat in RSV-associated pathogenesis. In conclusion, our preclinical data suggest that heparanase is a target for SARS-CoV-2 pathogenesis and that Roneparstat could serve as a novel dual-targeting agent for COVID-19. Human primary peripheral blood mononuclear cells (PBMCs) were acquired from deidentified donors at the Mississippi Valley Regional Blood Center. As determined by Washington University's HRPO (Human Research Protection Office) in 2009, these anonymous human blood cells are not considered human subject research. PBMCs were isolated using Ficoll-Paque Plus density gradient medium, at a density of 1.077 g/mL (catalog number 10771; Sigma), according to the manufacturer's instructions.

HIV-1 NLHX (CXCR4-tropic) or HIV-1 NLYU2 (CCR5-tropic) viral particles were made by transfecting 293T cells with HIV-1 NLHX or HIV-1 NLYU2 plasmids, as previously described (50) .

The replication-competent vesicular stomatitis virus (VSV)-SARS-CoV-2 chimeric virus expressing enhanced green fluorescent protein (eGFP) (VSV-eGFP-SARS-CoV-2), in which VSV G was replaced with the SARS-CoV-2 S gene, was generously provided by Sean Whelan (51) . A similar VSV-SARS-CoV-1 chimeric virus (VSV-eGFP-SARS-CoV-1) was also provided by Sean Whelan. Both VSV-eGFP-SARS-CoV-2 and VSV-eGFP-SARS-CoV-1 were grown in Vero-E6 cells.

Human macrophage differentiation. Human CD14 1 monocytes were purified from human PBMCs of healthy donors using CD14 1 beads (catalog number 130-050-201; Miltenyi Biotec), according to the manufacturer's instructions. Purified CD14 1 monocytes were cultured in minimal essential medium alpha (a-MEM) supplemented with 10% FBS and 20 ng/mL human recombinant macrophage colonystimulating factor (M-CSF) (catalog number 574804; BioLegend). Fresh media with M-CSF were changed every 3 days until the cells reached 70 to 80% confluence (days 12 to 14).

Human THP-1-derived macrophage differentiation. THP-1 macrophage differentiation was initiated by exposing the cells to 5 ng/mL phorbol-12-myristate-13-acetate (PMA) (catalog number 16561-29-8; Sigma-Aldrich) for 72 h. Subsequently, PMA was removed, and THP-1-derived macrophages were washed one time with phosphate-buffered saline (PBS) before S1 protein (0.5 mg/mL; GenScript, Piscataway, NJ) challenge. RNA or medium supernatants were harvested 12 h or 24 h after S1 protein challenge, respectively.

Inhibitors/drugs. Roneparstat (previously named SST0001 or 100 NA,RO-H) (18, 52) was kindly supplied by Leadiant Biosciences (Rome, Italy). A stock concentration of 50 mg/mL was prepared by solubilizing the drug in sterile water and stored at room temperature (up to 30 days). Heparin sodium salt from porcine intestinal mucosa (catalog number H3149; Sigma) was resuspended in PBS at a stock concentration of 25 mg/mL and stored at 4°C. The NF-k B inhibitor BAY 11-7082 (catalog number B5556; Sigma) was solubilized in dimethyl sulfoxide (DMSO) at a stock concentration of 50 mM and stored at 220°C.

SARS-CoV-2 infectivity assay. SARS-CoV-2 (USA-WA1/2020) was obtained from BEI Resources. USA-WA1/2020 was isolated from an oropharyngeal swab from a COVID-19 patient in Washington. Viral Together, this study demonstrated the potential use of Roneparstat as a dual-targeting therapy for COVID-19 to decrease viral infection and dampen the proinflammatory immune response mediated by macrophages. stocks were generated by infecting Vero-E6 cells at an MOI of 0.1 PFU. Both Roneparstat and heparin were subjected to 4-fold serial dilutions from 200 mg/mL to 0.003 mg/mL, and each dilution was mixed with the same volume of SARS-CoV-2 (16,000 PFU/mL). Next, the mixture was transferred to confluent Vero-E6 cells in 48-well plates. The final concentrations of Roneparstat and heparin were ;100 to 0.0015 mg/mL, and the virus dose was 400 PFU/well. After a 1-h inoculation at 37°C in a CO 2 incubator, the mixture was removed from each well, and fresh DMEM supplemented with 2% FBS and a different dose of Roneparstat or heparin (;100 to 0.0015 mg/mL) was added (200 mL/well). At 24 h postinfection, the cell culture supernatant from each well was harvested for virus titration by a plaque assay on Vero-E6 cells. The half-maximal inhibitory concentration (IC 50 ) was calculated based on the viral titer from the plaque assay. The infected Vero-E6 cell monolayer was fixed with 300 mL of 4% neutral buffered formaldehyde at room temperature for 2 h, followed by immunostaining with anti-SARS-CoV-2 S or N antibody. Percent inhibition was calculated with the formula % inhibition = 100 2 titer treated /titer untreated  100. The curve fit and IC 50 were generated by Prism 8 [log(inhibitor) versus normalized response 2 variable slope].

VSV-SARS-CoV-2 infectivity assay. Each compound was diluted serially, 4-fold, from 50 mg/mL to 0.0122 mg/mL and incubated with VSV-eGFP-SARS-CoV-2 or VSV-eGFP-SARS-CoV-1 for 1 h at 37°C. The compound-virus mixtures were used to inoculate Vero-E6 cells (MOI = 0.1) in 96-well plates and incubated at 37°C for 1 h, after which the mixture was replaced with 200 mL of DMEM with 2% FBS containing 50 mg/mL to 0.0122 mg/mL of each compound. At 10 h postinoculation, cells were fixed in 2% formaldehyde for 30 min at room temperature and replaced with PBS. Viral infectivity was measured by automated enumeration of GFP-positive cells from captured images using a Cytation 5 automated fluorescence microscope (BioTek) and analyzed using Gen5 data analysis software (BioTek). Percent inhibition was calculated as 100 2 green cells with compound treatment/green cells with no compound treatment  100. The IC 50 of each peptide was determined by Prism 8 [log(inhibitor) versus normalized response 2 variable slope].

Plaque assays for SARS-CoV-2, VSV-eGFP-SARS-CoV-2, and VSV-eGFP-SARS-CoV-1. Confluent Vero-E6 cells in 12-well plates were infected with 10-fold serial dilutions of SARS-CoV-2, VSV-eGFP-SARS-CoV-2, or VSV-eGFP-SARS-CoV-1 in FBS-free DMEM. After absorption for 1 h at 37°C, the inoculum was removed, and 1 mL of a MEM overlay containing 0.25% low-melting-point agarose, 2% FBS, 0.12% sodium bicarbonate, 25 mM HEPES (pH 7.7), 2 mM L-glutamine, 100 mg/mL of streptomycin, and 100 U/mL of penicillin was added. After incubation at 37°C for 2 days, wells were fixed with 10% neutral buffered formaldehyde for 2 h, the overlay was removed, the cells were stained with 0.05% (wt/vol) crystal violet, and the plaques were counted.

HTLV-1 infectivity assay. The infectivity of HTLV-1 was measured using the Jurkat-LTR-Luc reporter cell line as described previously (53) . Briefly, the HTLV-1-producing cell line MT-2 was irradiated using an HIV-1 infectivity assay. TZM-Blue reporter cells were pretreated with the inhibitor in a 48-well plate for 24 h, and CXCR4-or CCR5-tropic HIV-1 strains were then added in the presence of various doses of Roneparstat or the vehicle. At 48 h postinfection, infected TZM-Blue cells were collected and lysed with 0.2% Triton X-100 in PBS. Luciferase activities were measured and presented as RLU. For VSVg-HIV-1-luc pseudotyped virus production, 293T cells were cotransfected with pHIV-1-luc/Denv and pVSVg, and virus was collected at 72 h posttransfection, as previously described (54, 55) . U87/X4 or U87/R5 cells were seeded into a 48-well plate (2 Â 10 4 cells per well) and infected with VSVg-HIV-1-luc in the presence or absence of various amounts of Roneparstat. Infected cells were lysed in a solution containing 100 mL PBS and 0.5% Triton X-100 at 48 h postinfection and examined for luciferase activity. Each infection/ treatment was run in triplicates.

Lentivirus production and HPSE knockdown THP-1 cells. Lenti-X 293 cells were transfected with psPAX2, PMD2.G and plasmid of interest using Lipofectamine 3000 (Invitrogen), and the supernatant was harvested at 24 h posttransfection. For HPSE KD, short hairpin RNA (shRNA) constructs in pLKO.1 puro vectors were obtained from Sigma-Aldrich (luciferase shRNA [shLuc], 59-CAGAATCGTCGTATGCAGTGA-39; HPSE shRNA 1, 59-GAGGAGAAGTTACGGTTGGAA-39; HPSE shRNA 2, 59-CCCAAGAAGGAATCAACCTTT-39; HPSE shRNA 3, 59-GCGAGGAGATTCTGTAAACTT-39). THP-1 cells were infected with lentivirus overnight in the presence of 10 mg/mL protamine sulfate. At 24 h postinfection, transduced cells were selected with 2 mg/mL puromycin for 3 days. RNA or conditioned medium was harvested from macrophages challenged with SARS-CoV-2 S1 protein (0.5 mg/mL) for 12 h or 24 h, respectively.

Western blotting. Nuclear and cytoplasmic protein lysates were isolated from human macrophages using the NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific) supplemented with Halt protease inhibitor cocktail (Thermo Scientific) according to the manufacturer's protocol. Samples were separated on 4 to 20% Mini-Protean TGX precast protein gels (Bio-Rad) by SDS-PAGE and transferred onto Immobilon-P polyvinylidene difluoride (PVDF) membranes (EMD Millipore) overnight at 4°C. Membranes were incubated with NF-k B p65 (clone D14E12), TATA binding protein (TBP) (clone D5C9H), or b-actin (clone 13E5) primary antibodies (1:1,000; Cell Signaling), followed by horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (1:2,000; Cell Signaling). All antibodies were diluted in 1Â Trisbuffered saline (TBS)-Tween (TBST) with 5% bovine serum albumin (BSA). Bands were developed by enhanced chemiluminescence and quantified using ImageJ software.

Human macrophage immunocytochemistry (ICC) staining. Human PBMCs were resuspended in a-MEM (supplemented with 10% FBS and human recombinant M-CSF at 20 ng/mL) and seeded onto coverslips (number 1.5 coverslip, 13-mm glass diameter; VWR) in 24-well plates. Cells were cultured for 2 days, and the nonadherent cells were then removed by sequential washes with Dulbecco's PBS (DPBS) (Gibco). Fresh media with M-CSF were changed every 2 to 3 days until the cells reached 70 to 80% confluence (days 5 to 7). Cells were challenged with SARS-CoV-2 S1 (0.5 mg/mL) protein, with or without various doses of Roneparstat (50 mg/mL and 100 mg/mL), for 24 h. For immunostaining, each well was fixed with 4% paraformaldehyde (15 min at room temperature), followed by two washes with ice-cold TBS. Each coverslip was subsequently incubated with 0.2% Triton X-100 (Sigma) for 10 min, 10% goat serum (Cell Signaling) for 30 min, anti-human p65 primary antibody (1:700; Cell Signaling) overnight at 4°C, and Alexa Fluor 488-conjugated anti-rabbit antibody (1:400; Jackson ImmunoResearch) for 1 h, and nuclei were counterstained with 49,6-diamidino-2-phenylindole (DAPI) (catalog number 422801; BioLegend) for 5 min. Coverslips were mounted onto glass slides (VWR) with ProLong Gold antifade mountant (catalog number P10144; Life Technologies).

Confocal microscopy and nuclear p65 quantification. Slides were imaged with a confocal microscope (FluoView1200; Olympus) with a 40Â water immersion lens objective. Seven to ten high-power fields were captured under each treatment condition. To quantify the nuclear p65 signal, captured images were analyzed using the Fiji imaging processing package with standard plug-ins (56) . DAPI staining was used to determine nuclear segmentation and masking. Briefly, for each high-power field, binary image masks were created using a DAPI-positive single-channel image to define the nuclear region of interest (ROI). The image calculator was used to subtract the DAPI mask from the original p65 single-channel images to create images with p65 staining within the nuclear ROI. Image measurements of the p65 mean fluorescence intensities (MFIs) within the nuclear ROI were then determined by the mean gray value within the DAPI mask using an empirically derived threshold.

Quantitative real-time PCR (qRT-PCR) and primers. RNA was extracted from cells using an RNeasy kit (Qiagen), and cDNA was generated with qScript cDNA supermix (Quanta Bio). qPCR was performed with PerfeCTa SYBR green supermix reagent (Quanta Bio) on the Bio-Rad CFX96 machine, as previously described (57) Multiplex cytokine array. A bead-based human inflammatory cytokine array was performed using LEGENDplex human inflammation panel 1 (BioLegend). Human primary macrophages were cultured for 24 h in the presence of S protein, with or without various doses of Roneparstat (50 to 200 mg/mL). Twenty-five microliters of the conditioned medium from various conditions was used to measure the secreted cytokines in each sample, according to the instructions from the manufacturer. The measurement was performed on a FACSCalibur flow cytometer (BD), and the data were analyzed using LEGENDplex software (BioLegend).

Single-cell RNA sequencing analysis. The R package Seurat was used for data scaling, dimensionality reduction, clustering, differential expression analysis, and visualization (58) . First, the gene-barcode matrix was normalized using the LogNormalize method in the Seurat NormalizeData function with default parameters. Next, 2,000 variable genes were selected using the vst selection method in the Seurat FindVariableFeatures function. Subsequently, the filtered features were scaled using the Seurat ScaleData function with default parameters, where the two variables nCount_RNA and percent.mito were regressed out during the scaling process. The principal-component analysis (PCA) was performed using variable genes, and the top 50 principal components were used to perform UMAP, which maps cells into the two-dimensional space for visualization. Next, a k-nearest-neighbor-based clustering analysis was performed on the PCA-reduced data to identify cell clusters using the Seurat FindClusters function with the resolution set to 1.2. Based on the UMAP reduction results, the DimPlot and FeaturePlot functions in Seurat were respectively used to visualize the BALF cell clusters and highlight the HPSE gene expression levels across healthy control, moderate COVID-19, and severe COVID-19 samples (Fig. 3A) .

The FindAllMarkers function in Seurat was used to perform the differential expression analysis (59) . The Model-Based Analysis of Single Cell Transcriptomics (MAST) package was used in FindAllMarkers. For each of the major cell types, the averaged differential HPSE gene expression level was calculated for each COVID-19 sample relative to all of the healthy control cells (Fig. 3B) . The HPSE gene in each cell type was considered significant for a COVID-19 sample if the P value was ,0.05, adjusted by the false discovery rate using Bonferroni correction.

Macrophages were reintegrated with a new Seurat object. Macrophages from all samples were integrated using the top 50 dimensions of canonical correlation analysis and PCA, where the parameter k.filter was set to 115. Next, the average expression levels of the HPSE gene and the inflammatory cytokine genes IL6, TNF, IL1B, and CCL2 were calculated using the Seurat AverageExpression function with default parameters. Similarly, average expression levels for each of the healthy control, moderate COVID-19, and severe COVID-19 samples were generated (Fig. 3C) .

Statistical analysis. Experiments were analyzed using two-tailed Student's t test (2 groups), oneway analysis of variance (ANOVA) (.2 groups or repeated measures), or two-way ANOVA (two variables; the P value refers to the interaction) using Prism 8 (GraphPad Software, Inc.). A nonparametric Spearman correlation coefficient test was adopted to determine statistically significant correlations between two groups. Results were considered to reach significance at a P value of #0.05 and are indicated with asterisks in the figures (*, P # 0.05; **, P # 0.01; ***, P # 0.001; ****, P # 0.0001). Data are presented as mean values; error bars represent the standard errors of the means (SEM).

The 2020 pandemic: current SARS-CoV-2 vaccine development

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

Cytokine storm

Cell entry mechanisms of SARS-CoV-2

Viral targets for vaccines against COVID-19

SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2

Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias?

Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases

Heparanase: from basic research to therapeutic applications in cancer and inflammation

Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy

Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice

The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis

Heparanase, cell signaling, and viral infections

Increased plasma heparanase activity in COVID-19 patients

Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase

Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting

Roneparstat: development, preclinical and clinical studies

Phase I study of the heparanase inhibitor roneparstat: an innovative approach for multiple myeloma therapy

Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4 1 T cells

Cell membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Heparanase is required for activation and function of macrophages

NF-kappaB signaling in macrophages: dynamics, crosstalk, and signal integration

The deubiquitinase USP7 uses a distinct ubiquitin-like domain to deubiquitinate NF-kB subunits

Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin

Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions

Heparanase, heparan sulfate and viral infection

Heparanase is a host enzyme required for herpes simplex virus-1 release from cells

Viral activation of heparanase drives pathogenesis of herpes simplex virus-1

Disruption of innate defense responses by endoglycosidase HPSE promotes cell survival

Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma

Heparanase-regulated syndecan-1 shedding facilitates herpes simplex virus 1 egress

Heparanase regulates the M1 polarization of renal macrophages and their crosstalk with renal epithelial tubular cells after ischemia/reperfusion injury

Defining the innate immune responses for SARS-CoV-2-human macrophage interactions

Tocilizumab in hospitalized patients with severe Covid-19 pneumonia

Interleukin-6 receptor antagonists in critically ill patients with Covid-19

Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway

Pleiotropy and specificity: insights from the interleukin 6 family of cytokines

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study

Therapeutic anticoagulation with heparin in critically ill patients with Covid-19

Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19

Dexamethasone in hospitalized patients with Covid-19

Expression of heparanase in kidney of rats with respiratory syncytial virus nephropathy and its relationship with proteinurina

Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses

Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis

Quantitative analysis of human Tlymphotropic virus type 1 (HTLV-1) infection using co-culture with Jurkat LTR-luciferase or Jurkat LTR-GFP reporter cells

Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range

Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry

Fiji: an opensource platform for biological-image analysis

HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia

Integrating single-cell transcriptomic data across different conditions, technologies, and species

MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data

We thank Patrick Green and David Warren for their valuable expert suggestions and criticism. We thank Dennis Oakley, Crystal Idleburg, and Nitin Pokhrel for their technical assistance. We thank Sean Whelan for providing VSV-eGFP-SARS-CoV-2 for this study.Conception